MNG970
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.364
- PEROXISOME+0.297
- G2M_CHECKPOINT+0.283
- BILE_ACID_METABOLISM+0.245
- PROTEIN_SECRETION+0.197
- ANDROGEN_RESPONSE+0.174
- MITOTIC_SPINDLE+0.162
- UV_RESPONSE_DN+0.140
- P53_PATHWAY+0.129
- GLYCOLYSIS+0.127
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.421
- NOTCH_SIGNALING-0.399
- MYC_TARGETS_V2-0.338
- OXIDATIVE_PHOSPHORYLATION-0.327
- TNFA_SIGNALING_VIA_NFKB-0.293
- PANCREAS_BETA_CELLS-0.235
- UV_RESPONSE_UP-0.202
- COAGULATION-0.190
- ALLOGRAFT_REJECTION-0.179
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.165
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1076 | — | — | 0.736 |
| 2 | bf5f606f-17ae-46bb-b687-7863ab3d97b1 | — | — | 0.721 |
| 3 | TCGA-AR-A24N-01A-11R-A169-07 | — | B | 0.625 |
| 4 | MNG1184 | — | — | 0.622 |
| 5 | R397 | — | — | 0.603 |
| 6 | ERR2278878 | — | — | 0.597 |
| 7 | MNG611 | — | — | 0.579 |
| 8 | MNG649 | — | — | 0.578 |
| 9 | MNG821 | — | — | 0.564 |
| 10 | TCGA-OR-A5KO-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.560 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.364 | Inavolisib | — uncovered |
| PEROXISOME | 0.297 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.283 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.245 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.197 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.174 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.162 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.129 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.127 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.126 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.122 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.099 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.084 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.079 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.077 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.071 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.069 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.062 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.031 | Inavolisib | — uncovered |